CopyMark Law Group
4.9/5
Drawing for HIPSCORE

USPTO serial 98686425

HIPSCORE

Reviewed by CopyMark Law Group

Reg. 8091273Status 700Registered
Filing date
Status date
Registration date
Jan 6, 2026
Examiner
DIGAN,MATTHEW M
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with HIPSCORE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Gerard T. Gallagher

Gerard T. Gallagher Barnes & Thornburg LLP201 S. Main StreetSuite 400South Bend, IN 46601

Goods and services

ClassDescriptionStatusFirst use
005Tissues for surgical use being surgical implants comprised of living tissues based on human induced pluripotent stem cells; diagnostic agents and materials, namely, amplification primers for amplifying a gene specific for mesodermal cells or a part of a gene specific for mesodermal cells for medical and pharmaceutical use, in particular, for the analysis of human-induced pluripotent stem cells; diagnostic agents and materials, namely, amplification primers for amplifying a gene specific for mesodermal cells or a part of a gene specific for mesodermal cells for medical and pharmaceutical use using human-induced pluripotent stem cells; diagnostic agents and materials, namely, amplification primers for amplifying a gene specific for endodermal cells or a part of a gene specific for endodermal cells for medical and pharmaceutical use, in particular, for the analysis of human-induced pluripotent stem cells; diagnostic agents and materials, namely, amplification primers for amplifying a gene specific for endodermal cells or a part of a gene specific for endodermal cells for medical and pharmaceutical use using human-induced pluripotent stem cells; diagnostic agents and materials, namely, amplification primers for amplifying a gene specific for ectodermal cells or a part of a gene specific for ectodermal cells for medical and pharmaceutical use, in particular, for the analysis of human-induced pluripotent stem cells; diagnostic agents and materials, namely, amplification primers for amplifying a gene specific for ectodermal cells or a part of a gene specific for ectodermal cells for medical and pharmaceutical use using human-induced pluripotent stem cells; diagnostic agents and materials, namely, amplification primers for amplifying a gene specific for pluripotent cells or a part of a gene specific for pluripotent cells for medical and pharmaceutical use, in particular, for the analysis of human-induced pluripotent stem cells; diagnostic agents and materials, namely, amplification primers for amplifying a gene specific for pluripotent cells or a part of a gene specific for pluripotent cells for medical and pharmaceutical use using human-induced pluripotent stem cellsACTIVE—
042Scientific and technological services;, namely, scientific research, analysis, testing, and evaluation in the field of human-induced pluripotent stem cells; Scientific and technological services, namely, testing in the field of human-induced pluripotent stem cells; authentication in the field of human-induced pluripotent stem cells; quality control for others in the field of human-induced pluripotent stem cellsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 6, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 6, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 24, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 24, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Nov 24, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Nov 18, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 18, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 12, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 16, 2025PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Aug 26, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 26, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Aug 26, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 26, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 26, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 12, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 12, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 12, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 12, 2025XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
May 12, 2025XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Feb 13, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 13, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 13, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2025DOCKASSIGNED TO EXAMINER—
Jan 22, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 7, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance